Christopher Goetz to Longitudinal Studies
This is a "connection" page, showing publications Christopher Goetz has written about Longitudinal Studies.
Connection Strength
0.699
-
Visual plus nonvisual hallucinations in Parkinson's disease: development and evolution over 10 years. Mov Disord. 2011 Oct; 26(12):2196-200.
Score: 0.071
-
Racial differences may influence the role of cholecystokinin polymorphisms in Parkinson's disease hallucinations. Mov Disord. 2011 Aug 01; 26(9):1781-2.
Score: 0.070
-
Hallucinations and sleep disorders in PD: ten-year prospective longitudinal study. Neurology. 2010 Nov 16; 75(20):1773-9.
Score: 0.068
-
Cancer incidence in a trial of an antiapoptotic agent for Parkinson's disease. Mov Disord. 2010 Sep 15; 25(12):1801-8.
Score: 0.067
-
Comparison of tic characteristics between children and adults. Mov Disord. 2008 Dec 15; 23(16):2407-11.
Score: 0.060
-
Does seasonal variation affect hallucinations in PD? A longitudinal study. Mov Disord. 2006 Jun; 21(6):863-5.
Score: 0.050
-
Age-related influences on the clinical characteristics of new-onset hallucinations in Parkinson's disease patients. Mov Disord. 2006 Feb; 21(2):267-70.
Score: 0.049
-
Hallucinations and sleep disorders in PD: six-year prospective longitudinal study. Neurology. 2005 Jan 11; 64(1):81-6.
Score: 0.045
-
Prospective longitudinal assessment of hallucinations in Parkinson's disease. Neurology. 2001 Dec 11; 57(11):2078-82.
Score: 0.037
-
Prognostic Modeling of Parkinson's Disease Progression Using Early Longitudinal Patterns of Change. Mov Disord. 2021 12; 36(12):2853-2861.
Score: 0.036
-
Differential progression of motor impairment in levodopa-treated Parkinson's disease. Mov Disord. 2000 May; 15(3):479-84.
Score: 0.033
-
A practical approach to remote longitudinal follow-up of Parkinson's disease: the FOUND study. Mov Disord. 2014 May; 29(6):743-9.
Score: 0.021
-
Movement disorder society unified Parkinson disease rating scale experiences in daily living: longitudinal changes and correlation with other assessments. Mov Disord. 2013 Dec; 28(14):1980-6.
Score: 0.021
-
A longitudinal program for biomarker development in Parkinson's disease: a feasibility study. Mov Disord. 2009 Oct 30; 24(14):2081-90.
Score: 0.016
-
Serum urate as a predictor of clinical and radiographic progression in Parkinson disease. Arch Neurol. 2008 Jun; 65(6):716-23.
Score: 0.014
-
Progression of Parkinson's disease without levodopa. Neurology. 1987 Apr; 37(4):695-8.
Score: 0.013
-
Objective assessments of longitudinal outcome in Gilles de la Tourette's syndrome. Neurology. 2003 Oct 14; 61(7):936-40.
Score: 0.010
-
Longitudinal outcome of Parkinson's disease patients with psychosis. Neurology. 2003 Jun 10; 60(11):1756-61.
Score: 0.010
-
Metric properties of nurses' ratings of parkinsonian signs with a modified Unified Parkinson's Disease Rating Scale. Neurology. 1997 Dec; 49(6):1580-7.
Score: 0.007